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Antibodies to the extreme C-terminal region of human progastrin have been used to monitor the isolation 
of high-M, immunoreactive material in a gastrinoma extract. Microsequence analysis of the product re- 
vealed amino acid residues in the first 18 positions corresponding to those predicted from the cDNA sequen- 
ce for preprogastrin starting at position 22; the sequence and immunochemical data together allow the iden- 
tification of this material as intact progastrin. Implications for gastrin biosynthesis are discussed. 
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1. INTRODUCTION 
It is now known from cDNA sequencing that the 
human gastric acid-stimulating hormone gastrin is 
initially synthesized as a precursor of 101 residues 
[l-3]. The precursor contains a single copy of the 
34-residue peptide, big gastrin (G34), which is the 
largest chemically characterized form of the hor- 
mone. In antral gastrin cells there is evidence that 
tryptic-like cleavage of the precursor liberates 
flanking peptides at the C- and N-terminus of G34, 
and cleaves G34 to give G17, which is the major 
biologically active form of the hormone, and an N- 
terminal fragment (NT G34) [4-61. It seems, 
however, that different biosynthetic processing 
pathways occur in other gastrin-producing tissues, 
e.g. human duodenum and gastrinomas [6]. To 
study the mechanisms of post-translational 
modification in more detail we have recently 
developed antibodies to a range of peptides likely 
to be derived from the precursor. One of these is 
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specific for the extreme C-terminal region of the 
intact precursor and in some gastrinomas this an- 
tibody reveals abundant quantities of material with 
apparently high M, [6]. We report here the isola- 
tion of this material together with evidence that it 
corresponds to intact progastrin and that it also oc- 
curs in antral mucosa. 
2. MATERIALS AND METHODS 
2.1. Isolation of progastrin 
The starting material for the present isolation 
was a large liver metastasis obtained at surgery 
from a gastrinoma patient. Fresh tissue (21 g)_was 
quickly added to boiling water (210 ml), heated for 
10 min to inactivate proteases, and then 
homogenised. The extract was centrifuged twice 
(3000 x g, 15 min, 4”C, followed by 13000 x g, 
30 min), and to the supernatant was added 
chloroform (2 ~01s) and methanol (1 vol.); the ex- 
tract was then centrifuged and the aqueous layer 
lyophilised. Approx. 200 mg of the resulting 
powder (corresponding to about 10 g tissue) was 
dissolved in distilled water, centrifuged (50000 x 
g, 30 min) and fractionated by gel filtration on 
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Sephadex G-50 (2.5 x 100 cm) in 0.05 M am- 
monium bicarbonate. Tubes containing im- 
munoreactive material of apparently high h4, were 
reduced in volume and an aliquot corresponding to 
approx. 10% of the total was purified by HPLC on 
a yBondapak Crs cartridge in a Waters Z-module 
using an Altex system and gradient elution with 
acetonitrile and 0.1% aqueous trifluoroacetic acid 
(TFA). A final purification was made on a Vydac 
5 ym Cl8 (5 X 250 mm) COhIIIn using a similar 
system. For analytical studies, extracts of five 
other gastrinomas resected at surgery, and of an- 
tral mucosa (n = 5) resected from patients 
undergoing antrectomy for duodenal ulcer, were 
prepared by boiling in water, and fractionated by 
gel filtration and HPLC on Techsil 5 ,um Crs (5 x 
250 mm) using conditions similar to those de- 
scribed above. The radioimmunoassay (RIA) used 
to monitor purification has been detailed in [6]. It 
employe an antibody raised to synthetic Tyr-Ala- 
Glu-Asp-Glu-Asn, which corresponds to (Tyr) 
progastrin 97-101 (the predicted extreme C- 
terminal pentapeptide of the precursor); the same 
peptide was used for radiolabelling and as 
standard. 
2.2. Structural studies 
Microsequence analysis was carried out using an 
Applied Biosystems gas-phase sequencer (470 A) 
and identification of phenylthiohydantoin (PTH) 
derivatives was made by HPLC. Possible post- 
translational modifications of the precursor in the 
form of sulphation and phosphorylation were ex- 
amined by: (i) incubation with arylsulphatase (200 
or 400rg) in sodium acetate for 2 h at 37°C [7], 
followed by trypsinization, HPLC separation (Cl8 
Techsil5 pm) and identification of G17-containing 
tryptic peptides by N-terminal specific RIA [8]; (ii) 
phosphate determination by the malachite green 
method [9]. 
3. RESULTS AND DISCUSSION 
In RIA, antibodies specific for the extreme C- 
terminus of progastrin revealed two major peaks 
of immunoreactivity when the gastrinoma extract 
was fractionated on Sephadex G-50 (inset, fig.1). 
The earlier eluting material emerged as a single ma- 
jor peak when it was further purified by HPLC 
(fig.1). A second HPLC step on Vydac CIS gave a 
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Fig.1. Reversed-phase paration on HPLC of a 
gastrinoma extract. The major peak (retention time 
28 min) reacts with antibodies to the C-terminus of 
progastrin. The gastrinoma extract was fractionated first 
on Sephadex G-50 (2.5 x 100 cm) in 0.05 M ammonium 
bicarbonate when two peaks of immunoreactivity were 
identified (see inset; -, Azso; ---, 
immunoreactivity, nmol. ml-‘, abscissa: fraction 
number, volume 5.5 ml). The earlier eluting peak in the 
Sephadex eluate was applied topBondapak Cl8 cartridge 
in a Waters Z module and eluted with an acetonitrile 
gradient (- - -) from 0.1% aqueous TFA. Further 
separation on Vydac Cl8 gave a homogeneous peptide 
for sequencing. 
homogeneous peptide suitable for amino acid 
analysis. Recovery was >75% at each step. RIA 
indicated that 9.5 nmol of the final product was 
obtained, and this agrees well with an estimate of 
11 .O nmol determined by &se. The latter estimate 
is based on the calculated molar extinction coeffi- 
cient for a peptide with three tryptophan and one 
tyrosine residue (as predicted from the cDNA se- 
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Fig.2. Amino acid sequence of the gastrinoma peptide (see fig.1) determined by gas-phase microsequence analysis. PTH 
amino acids were identified for 18 cycles; at cycle 15 both Gly and Thr were observed. Shown above is the amino acid 
sequence of progastrin predicted from cDNA sequencing [l-3] starting at position 20. 
quence). This yield is equivalent to an original 
tissue concentration of about 10 nmol/g which 
represents an overall recovery of 25% from the in- 
itial boiling water extract. The final solution was 
reduced to about 150 ~1 with a stream of nitrogen 
and 40~1 was taken for sequencing. Gas-phase 
microsequence analysis produced identifiable PTH 
amino acids for 18 cycles. The amino acid se- 
quence obtained was identical to that predicted 
from the cDNA sequence of human preprogastrin 
starting at residue 22 (fig.2). There was a single 
ambiguity at cycle 15 when both Gly and Thr were 
observed. The latter is predicted, and the former 
may represent carry over from the previous cycle. 
The C-terminal extent of the peptide can be de- 
duced from the fact that it reacts with antibodies 
specific for the predicted sequence of the extreme 
C-terminus of the precursor. Assuming the signal 
peptide corresponds to residues 1-21 of 
preprogastrin, the sequence and immunochemical 
data therefore allow us to identify the present pep- 
tide as corresponding to intact progastrin. The 
second major peak in Sephadex gel filtration 
eluates (fig.1) probably corresponds to the C- 
terminal fragment of the precursor produced when 
it is cleaved to yield G34 and G17; on the HPLC 
system shown in fig.1 this material was not re- 
tained and was eluted with 0.1% TFA. 
The material isolated from tumours also occurs 
in normal antrum. HPLC of the appropriate frac- 
tions of Sephadex G-50 columns of antral mucosa 
revealed a major peak in the same position as the 
gastrinoma progastrin. In three of five antral 
samples examined there was also a second peak 
with a lower retention time (25 min, fig.3) that ac- 
counted for l-30% of total immunoreactivity in 
the sample. The identity of this material is present- 
ly unknown. It was absent from the gastrinoma 
used for the present isolation work, but was found 
in 2 of 5 other gastrinomas (20 and 50% of total). 
Peptides derived from preprogastrin are known 
to be modified by sulphation (G17) or 
phosphorylation (extreme C-terminal flanking 
peptide); it was of interest therefore to see if the 
gastrinoma material was so modified. Digestion 
with arylsulphatase did not change the elution 
position of either the intact progastrin, or the N- 
terminal G17-immunoreactive fragment generated 
by trypsinization, suggesting that the tyrosine 
residue in the G17 region of the precursor is not 
sulphated. However, microphosphate analysis in- 
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Fig.3. Separation on a Techsil C~S column of the 
immunoreactive material in an antral extract and in the 
extract of gastrinoma used for isolation studies (figs 
1,2). In both cases the material was fractionated first on 
Sephadex G-SO and the early eluting peak reacting with 
C-terminal specific progastrin antibodies was taken for 
reversed-phase HPLC using a gradient of 0.1% aqueous 
TFA and acetonitrile (- - -). Note that the major peaks 
coincide (36 min), and the presence of a minor peak 
(retention time 25 min) in the antral extract. 
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dicated that in 5.1 nmol progastrin there was 
1.8 nmol phosphate, so that about 30% of the 
precursor would appear to be phosphorylated. The 
C-terminal flanking peptide of porcine progastrin 
has recently been shown to occur in both 
phosphorylated and unphosphorylated forms [lo] 
and the homologous Ser in the C-terminal region 
of human progastrin is therefore a plausible can- 
didate for the site of phosphorylation. 
A variety of intermediates and products of pro- 
gastrin processing have now been identified; these 
include, in addition to G17 and G34, Gly-extended 
G17 and G34, NT G34 and the C- and N-terminal 
flanking peptides [4,5,1 l-131. However, the 
precise sequence of events involved in the produc- 
tion of these forms remains in doubt. Since they 
differ in both distribution and biological proper- 
ties the factors regulating their production are of 
physiological importance. The capacity to identify 
the intact gastrin precursor now makes it possible 
to study post-translational processing mechanisms 
in detail. Moreover, the present method of isola- 
tion should make it possible to obtain sufficient 
material to raise progastrin-specific antibodies. 
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